Recent Updates — WINT

Windtree Therapeutics signed an agreement on December 16, 2025, to sell its cardiovascular drug candidates to Seismic Pharmaceutical Operations, LLC. The transaction includes a $150,000 closing cash payment, the transfer of cardiovascular development payables to the buyer, and a contingent payment of $700,000 if the buyer completes a financing round of at least $10 million. Windtree retains a right to 20% of any future milestone payments, royalty payments, or global commercial net revenues from the assets. The company operates in the biotechnology industry and develops drug candidates for various medical conditions.